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[0001] The present invention refers to a method for diagnosis or determining prognosis of osteoarthritis and/or subchon-
dral bone sclerosis and osteomodulin and fragments thereof as biomarkers for osteoarthritis and use thereof.
[0002] Osteoarthritis (OA) is the most common joint disease and is a major cause of joint pain and disability in the
aging population. Its etiology is multifactorial (i.e., age, obesity, joint injury, genetic predisposition), and the pathophys-
iologic process affects the entirety of the joint. Destruction of articular cartilage, sclerosis of subchondral bone, and
formation of osteophytes, synovial inflammation, and ligament and meniscal damage constitute the main features char-
acterizing OA.
[0003] Besides finding management strategies for OA, the challenge is also to identify tools that could help the prog-
nosis, the diagnosis and monitoring of disease progression and assess the efficacy of new therapeutic interventions.
These tools need to be accurate and sensitive enough to identify early event at the molecular level and objectively
assess the efficacy of novel or pre-existing therapeutic modalities. Soluble biomarkers are likely to be among these tools.
[0004] So far, only cartilage-derived biomarkers are used in osteoarthritis. Mainly used are fragments coming from
Type II collagen (Coll2-1, Coll2-1NO2, C2C, PIINP, CTXII), aggrecan (MMPs or ADAMTSs generated neoepitopes,
Keratan sulfate or CS846), COMP or Fibulin-3.
[0005] Osteomodulin is known from the art, particularly by NINOMIYA ET AL in BIOCHEMICAL AND BIOPHYSICAL
RESEARCH COMMUNICATIONS, Academic Press Inc Orlando US 362(2) 2007, but is not known as osteoarthritis
biomarker. Poyclonal Antibodies of osteomdulin are described in WO 2010/046443 published on 29 April 2010, but not
their use in in-vitro prognosis and/or diagnosis of osteoarthritis.
[0006] Bay-JENSEN A C ET AL in Osteoarthritis and Cartilage 24(1) 2016 p9-20, describes a list of biomarkers for
osteoarthritis, but the list does not disclose osteomodulin. SANCHEZ-SABATE E ET AL in Osteoarthritis and Cartilage
17(8) 2009 p1106-1114 describes the decrease of osteomodulin in patients of group E compared to patients of group
C. But patients of group E and C are not affected by osteoarthritis.
[0007] Furthermore, currently no single specific marker is able to prognose and/or diagnose precisely the pathology.
Therefore, at present a combination of different markers reflecting different aspects of the pathology has to be used.
Indeed, OA is a heterogeneous syndrome with different clinical phenotypes defined by risk factors, progression profiles,
co-morbidities, signs and symptoms. In current diagnostic methods for in osteoarthritis only cartilage-derived biomarkers
are used.
[0008] Therefore, the technical object of the present invention was to provide a new marker, a single specific marker
and a method for prognosing and diagnosing precisely the pathology of osteoarthritis.
Summary of the present invention
[0009] When pursuing the studies of the present invention the present inventors discovered that osteomodulin is less
expressed and less secreted by sclerotic subchondral osteoblasts during osteoarthritis (OA). Further, the present in-
ventors found fragments of osteomodulin in body fluids, in particular in serum, of OA patients, and that serum concen-
trations of the osteomodulin fragments were lower than compared to those of healthy individuals.
[0010] Therefore, the present invention provides the following (1) to (9):
(1) Use of Osteomodulin (OMD) protein or fragment of osteomodulin (OMD) protein in in-vitro prognosis and/or
diagnosis of osteoarthritis and/or subchondral bone sclerosis of mammals, preferably human individuals wherein
full-length osteomodulin protein is having the amino acid sequence shown in SEQ ID NO: 1,
wherein osteomodulin (OMD) protein is a protein represented by the amino acid positions 1-421 or by the amino
acid positions 21-421 of SEQ ID NO: 1; and
wherein said fragment is selected from the group consisting of a) and b)
a) OMD-(131-223),
b) OMD-(236-296).
(2) Use of Osteomodulin (OMD) protein or fragment of osteomodulin (OMD) protein according to (1), wherein
decreased expression or decreased concentration in body fluids of said osteomodulin protein or its fragment(s)
compared to healthy individuals indicate onset of osteoarthritis and/or subchondral bone sclerosis.
(3) Use of Osteomodulin (OMD) protein or fragment of osteomodulin (OMD) protein according to (2), wherein said
decreased expression or decreased concentration is measured in body fluids selected from the group consisting of
urine, secretions, interstitial fluid, blood, synovial fluid, serum, spinal fluid lymph, preferably serum. Decreased body
fluid levels, in particular decreased serum levels, of said osteomodulin (OMD) protein or said fragment(s) compared













to healthy individuals indicate onset of osteoarthritis and/or subchondral bone sclerosis.
(4) Method for prognosis and/or diagnosis of osteoarthritis and/or subchondral bone sclerosis, comprising the fol-
lowing steps:
i) measuring osteomodulin (OMD) protein or a fragment or fragments of osteomodulin (OMD) protein in samples
of body fluids of mammalian individuals, preferably human serum samples;
ii) judging that decreased levels of osteomodulin (OMD) protein or of said fragment(s) compared to levels in
body fluids, preferably serum, of healthy individuals indicate onset of osteoarthritis and/or subchondral bone
sclerosis
wherein full-length osteomodulin protein is having the amino acid sequence shown in SEQ ID NO: 1,
wherein osteomodulin (OMD) protein is a protein represented by the amino acid positions 1-421 or by the amino
acid positions 21-421 of SEQ ID NO: 1; and
wherein said fragment is selected from the group consisting of a) and b)
a) OMD-(131-223),
b) OMD-(236-296).
(5) Method for determining or checking or diagnosis of the therapeutic effect of treatment of osteoarthritis and/or
subchondral bone sclerosis in a mammalian individual, preferably a human individual, comprising the following steps:
i) measuring osteomodulin (OMD) protein or a fragment or fragments of osteomodulin (OMD) protein in samples
of body fluids, preferably serum samples, of said individual during or after treatment;
ii) judging that either one of (1) to (3)
(1) normal levels of osteomodulin (OMD) protein or of said fragment(s) in the samples obtained in step i), or
(2) increased levels of osteomodulin (OMD) protein or of said fragment(s) in said samples obtained in step
i) compared to levels in samples of body fluids, preferably serum samples, of said individual before said
treatment, or
(3) increased levels of osteomodulin (OMD) protein or of said fragment(s) in said samples obtained in step
i) compared to levels in samples of body fluids, preferably serum samples, of healthy individuals,
indicate a therapeutic effect of the treatment of osteoarthritis and/or subchondral bone sclerosis in said individual
wherein full-length osteomodulin protein is having the amino acid sequence shown in SEQ ID NO: 1,
wherein osteomodulin (OMD) protein is a protein represented by the amino acid positions 1-421 or by the amino
acid positions 21-421 of SEQ ID NO: 1; and
wherein said fragment is selected from the group consisting of a) and b)
a) OMD-(131-223),
b) OMD-(236-296).
In preferred methods according to any one of (4) to (5) for measuring the body fluid levels, preferably serum levels,
in step i) an immunological binding partner is used which is selected from the group consisting of polyclonal antibodies,
monoclonal antibodies, humanized antibodies, Fc fragments, Fab fragments, single chain antibodies (scFv), chimeric
antibodies, biobetters and other antigen-specific antibody fragments.
(6) Fragment of osteomodulin protein, wherein full-length osteomodulin protein is having the amino acid sequence
shown in SEQ ID NO: 1, and wherein said fragment is selected from the group consisting a) to b):
a) OMD-(131-223),
b) OMD-(236-296),
(7) Use of Immunological binding partner specifically binding to osteomodulin (OMD) protein or fragment of osteo-
modulin (OMD) protein for use in the prognosis and/or diagnosis of osteoarthritis and/or subchondral bone sclerosis
of mammals, preferably human individuals
wherein full-length osteomodulin protein is having the amino acid sequence shown in SEQ ID NO: 1, and wherein
said fragment is selected from the group consisting of a) and b):















(8) Immunological binding partner specifically binding to an osteomodulin fragment, wherein full-length osteomodulin
protein is having the amino acid sequence shown in SEQ ID NO: 1, and wherein said fragment is selected from the
group consisting a) to b):
a) OMD-(131-223),
b) OMD-(236-296).
In preferred embodiments of the immunological binding partner according to (8) the immunological binding partner
is selected from the group consisting of polyclonal antibodies, monoclonal antibodies, humanized antibodies, Fc
fragments, Fab fragments, single chain antibodies (scFv), chimeric antibodies, biobetters and other antigen-specific
antibody fragments.
(9) Use of a Kit comprising the immunological binding partner according to 7 or 8
wherein said immunological binding partner preferably is selected from the group consisting of polyclonal antibodies,
monoclonal antibodies, humanized antibodies, Fc fragments, Fab fragments, single chain antibodies (scFv), chimeric
antibodies, biobetters and other antigen-specific antibody fragments.
Detailed description of the invention
[0011] The invention is described in the appended claims.
[0012] The present invention provides osteomodulin and fragments thereof as a single specific marker that is able to
determine prognose and/or to diagnose precisely the pathology of OA. In particular the present invention provides
osteomodulin (OMD) protein or fragment of osteomodulin protein for use in the prognosis and/or diagnosis of osteoarthritis
and/or subchondral bone sclerosis of mammals, preferably human individuals. In particular, a method is provided for
prognosis and/or diagnosis of osteoarthritis and/or subchondral bone sclerosis, using osteomodulin (OMD) protein or
fragment(s) of osteomodulin protein as a marker for the prognosis and/or diagnosis of osteoarthritis and/or subchondral
bone sclerosis of mammals, preferably human individuals. In particular, the osteomodulin (OMD) protein or fragment of
osteomodulin (OMD) protein are used in said prognosis and/or diagnosis in that way that decreased expression or
decreased concentration in body fluids of said osteomodulin protein or its fragment(s) compared to healthy individuals
indicate onset of osteoarthritis and/or subchondral bone sclerosis. In a further preferred embodiments decreased ex-
pression or decreased concentration is measured in body fluids selected from the group consisting of urine, secretions,
interstitial fluid, blood, synovial fluid, serum, spinal fluid lymph, more preferably serum.
[0013] The method according to the present invention comprises i) measuring osteomodulin (OMD) protein or a frag-
ment or fragments of osteomodulin (OMD) protein in samples of body fluids of mammalian individuals, preferably human
serum samples; ii) judging that decreased levels of osteomodulin (OMD) protein or of said fragment(s) compared to
body fluids levels, preferably serum levels, of healthy individuals indicate onset of osteoarthritis and/or subchondral bone
sclerosis.
[0014] Osteomodulin is an extracellular matrix keratan sulfate proteoglycan member of the small leucine-rich repeat
protein family. For some time osteomodulin was thought to be bone specific but recently osteomodulin expression was
also observed in other articular tissues like articular chondrocytes and labrum-derived fibrochondrocytes. Little is known
about the biological activity of osteomodulin. It may be implicated in biomineralization processes and has a function in
binding of osteoblasts via the alpha(V)beta(3)-integrin. Osteomodulin is able in vitro to stimulate aggrecan expression
by articular chondrocytes. The mature form of osteomodulin of Homo sapiens is represented by the amino acid sequence
21-421 of SEQ ID NO: 1. The amino acid sequence shown in SEQ ID NO: 1 of the sequence listing of this application
also includes amino acid positions 1 to 20. The mature form of the protein has a molecular weight of 49.5 kDa but
depending to the glycosylation pattern it’s estimated around 60 to 85 kDa. The COOH terminal peptide binds to the bone
hydroxyapatite.
[0015] During the studies for the present invention the present inventors identified by using proteomic techniques
osteomodulin and fragments thereof as new possible soluble biomarkers coming from the secretome of primary subchon-
dral osteoblasts. The present inventors found that osteomodulin is less expressed and less secreted by sclerotic subchon-
dral osteoblasts during OA. Moreover, fragments of osteomodulin were found in human serum. Serum concentrations
of the osteomodulin fragments were found to be significantly lower than those of healthy individuals.
[0016] The data and in vitro results obtained suggest that osteomodulin can be considered to represent a potential
biomarker of osteoarthritis, or of a subset of osteoarthritis patients with subchondral bone changes. Quantifying osteo-
modulin or osteomodulin fragment level in serum indicates a particular state of the disease and can be used in diagnosis













and prognosis of osteoarthritis and or other ageing-related diseases, and also in monitoring the efficacy of treatment for
osteoarthritis and/or ageing-related diseases. The method of the present invention for prognosis and/or diagnosis of
osteoarthritis and/or subchondral bone sclerosis, as well as the method for determining or checking or diagnosis of the
therapeutic effect of treatment of osteoarthritis and/or subchondral bone sclerosis in a mammalian individual, makes
use of osteomodulin (OMD) protein or preferably fragment(s) of osteomodulin protein as a marker for the prognosis
and/or diagnosis of osteoarthritis and/or subchondral bone sclerosis of mammals. These fragments are selected from
the group consisting of a) to b).
a) OMD-(131-223) (OMD1 131-KIDYGVFAKLPNLLQLHLEHNNLEEFPFPL
PKSLERLLLGYNEISKLQTNAMDGLVNLTMLDLCYNYLHDSLLKDKIFAKMEKLMQL NLCSNR-223 (SEQ ID NO:
2)),
b) OMD-(236-296) (OMD2 236-MYLSLENNSISSIPEKYFDKLPKLHTLRMSHNK LQDIPYNIFNLPNIVELSVGHN-
KLKQAF-296 (SEQ ID NO: 3)).
[0017] Quantification of serum OMD1, OMD2, could also be used for the diagnostic of OA and the follow-up of anti-
OA therapies. Further, as OA is a heterogeneous syndrome with different clinical phenotypes, osteomodulin fragments
could be used in combination with other OA biomarkers to improve the knowledge of the patient disease and give
information to do personalized medicine. In addition, OMD1, OMD2, , can also be used as a marker of sclerotic subchon-
dral pre-osteoblasts and osteoblasts.
[0018] Although it is not yet clear if it precedes or occurs subsequently to cartilage damage, subchondral bone sclerosis
is an important feature in OA pathophysiology. Subchondral bone sclerosis is characterized by local bone resorption
and the accumulation of weakly mineralized osteoid substance. Subchondral bone sclerosis is suspected to be linked
to cartilage degradation, not only in modifying the mechanical properties of the subchondral bone, but also by releasing
biochemical factors with an activity on cartilage metabolism. The present inventors have previously demonstrated that
osteoblasts isolated from subchondral OA bone expressed an altered phenotype. More precisely, it was demonstrated
that osteoblasts coming from the thickening (called sclerotic, SC) of subchondral bone located just below a cartilage
lesion exhibits an elevated alkaline phosphatase (AP) activity and express higher levels of IL-6, IL-8, PGE2, TGF-β1
and type I collagen than osteoblasts coming from the non-thickening neighboring area (called non-sclerotic area, NSC).
During the studies of the present invention this in vitro model was used to compare the secretome of NSC and SC
osteoblasts.
Description of the Figures
[0019]
Figure 1 shows osteomodulin gene expression by pre-osteoblasts or mature osteoblasts in non sclerotic or sclerotic
cells. The mRNA copy numbers were normalized against the corresponding copy number of HPRT mRNA and
results are the mean 6 SEM of five independent experiments performed with bone biopsy coming from different
donors. In each experiment, each experimental condition was performed in duplicate. Comparison of mean values
was performed by paired t-test. The results showed that osteomodulin is less expressed by sclerotic osteoblasts
than non sclerotic osteoblasts.
Figure 2 shows a Western-blotting detection of osteomodulin using goat polyclonal antisera raised against entire
osteomodulin. rhOMD: human recombinant osteomodulin (positive control), DMEM: concentration unconditioned
culture supernatant (negative control), NSC: non sclerotic osteoblasts supernatant, SC: sclerotic osteoblasts su-
pernatant, s59, s67, s62: serum of three healthy patients.
Figure 3 shows the results of ELISA tests using antibodies against OMD1 and OMD2 peptide fragments. The figure
shows the OMD1 and OMD2 concentration in non sclerotic or sclerotic pre-osteoblasts and osteoblasts culture
supernatant. With this ELISA test fragments in osteoblasts culture supernatant were detected, and also the decrease
of OMD1 and OMD2 in sclerotic secretome compared to non sclerotic secretome was confirmed.
Figure 4 shows the results of the analysis of levels of OMD1 and OMD2 in human serum. 33 healthy and 24 OA
patients were quantified. In the healthy population, 11 were 20-30 years-old, 12 were 31-45-years-old and 10 were
46-65 years-old. The age range in OA population was 44-83 years. OMD1 and OMD2 were both significantly lower
in OA compared to healthy patients.
Figure 5 shows the quantification of OMD1 and OMD2 in serum of a guinea pig spontaneous model of OA.














[0020] As used herein "osteomodulin protein" or "OMD" refers to Homo sapiens osteomodulin represented by the
amino acid sequence 1-421 of SEQ ID NO: 1. In preferred embodiments "osteomodulin protein" or "OMD", in particular
"osteomodulin protein" or "OMD" for use in the prognosis and/or diagnosis of osteoarthritis and/or subchondral bone
sclerosis, refers to the mature form of osteomodulin of Homo sapiens represented by the amino acid sequence 21-421
of SEQ ID NO: 1.
[0021] By "sample" is intended any biological sample obtained from an organism, in particular body fluids which
contains, or is suspected to contain, a polypeptide or peptide selected from SEQ ID NOs: 1 to 5, preferably SEQ ID
NOs: 2 to 5. As indicated, biological samples include body fluids which contain the polypeptides and/or peptides, and
other tissue sources found to express the polypeptides and/or peptides. Methods for obtaining tissue biopsies and body
fluids from organisms are well known in the art. Samples from the body fluids such as urine, secretions, interstitial fluid,
blood, synovial fluid, serum, spinal fluid lymph, are particularly preferred and serum is most preferred.
[0022] The term "immunological binding partner" or "antibody" is used synonymously and is used in the broadest
sense and specifically covers, for example, polyclonal antibodies, monoclonal antibodies, humanized antibodies, Fc
fragments, Fab fragments, and antibody fragments that exhibit the desired biological or immunological activity, single
chain antibodies (scFv), chimeric antibodies, biobetters or other antigen-specific antibody fragments specifically binding
to polypeptides and peptide shown in SEQ ID NOs: 1 to 5, preferably SEQ ID NOs: 2 to 5. The term "immunoglobulin"
(Ig) is used interchangeable with "antibody" herein.
[0023] The term "monoclonal antibody" as used herein refers to an antibody obtained from a population of substantially
homogenous antibodies, i.e., the individual antibodies comprising the population are identical except for possibly naturally
occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed
against a single antigenic site. Furthermore, in contrast to polyclonal antibody preparations which include different
antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single
determinant on the antigen. In addition to their specificity, the monoclonal antibodies are advantageous in that they may
be synthesized uncontaminated by other antibodies. The modifier "monoclonal" is not to be construed as requiring
production of the antibody by any particular method. For example, the monoclonal antibodies useful in the present
invention may be prepared by the hybridoma methodology or may be made using recombinant DNA methods in bacterial,
eukaryotic animals or plant cells or may be isolated from phage antibody libraries.
[0024] The monoclonal antibodies herein include "chimeric" antibodies in which a portion of the heavy and/or light
chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or
belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous
to corresponding sequences in antibodies derived from another species or belonging to another antibody class or
subclass, as well as fragments of such antibodies, so long as they exhibit the desired biological activity. Chimeric
antibodies of interest herein include "primatized" antibodies comprising variable domain antigen-binding sequences
derived from a non-human primate (e.g. Old World Monkey, Ape etc), and human constant region sequences.
[0025] An "intact" antibody is one which comprises an antigen-binding site as well as a CL and at least heavy chain
constant domains CH1, CH2 and CH3.
[0026] "Antibody fragments" comprise a portion of an intact antibody, preferably the antigen binding or variable region
of the intact antibody. Examples of antibody fragments include Fab, Fab’, F(ab’)2, and Fv fragments; diabodies; linear
antibodies; single-chain antibody molecules; and multispecific antibodies formed from antibody fragments.
[0027] Papain digestion of antibodies produces two identical antigen-binding fragments, called "Fab" fragments, and
a residual "Fc" fragment, a designation reflecting the ability to crystallize readily. The Fab fragment consists of an entire
L chain along with the variable region domain of the H chain (VH), and the first constant domain of one heavy chain
(CH1). Each Fab fragment is monovalent with respect to antigen binding, i.e., it has a single antigen-binding site. Pepsin
treatment of an antibody yields a single large F(ab’)2 fragment which roughly corresponds to two disulfide linked Fab
fragments having divalent antigen-binding activity and is still capable of cross-linking antigen. Fab’ fragments differ from
Fab fragments by having additional few residues at the carboxy terminus of the CH1 domain including one or more
cysteines from the antibody hinge region. Fab’-SH is the designation herein for Fab’ in which the cysteine residue(s) of
the constant domains bear a free thiol group. F(ab’)2 antibody fragments originally were produced as pairs of Fab’
fragments which have hinge cysteines between them. Other chemical couplings of antibody fragments are also known.
[0028] The Fc fragment comprises the carboxy-terminal portions of both H chains held together by disulfides. The
effector functions of antibodies are determined by sequences in the Fc region, which region is also the part recognized
by Fc receptors (FcR) found on certain types of cells.
[0029] "Fv" is the minimum antibody fragment which contains a complete antigen-recognition and -binding site. This
fragment consists of a dimer of one heavy- and one light-chain variable region domain in tight, non-covalent association.
From the folding of these two domains emanate six hypervariable loops (3 loops each from the H and L chain) that
contribute the amino acid residues for antigen binding and confer antigen binding specificity to the antibody. However,













even a single variable domain (or half of an Fv comprising only three CDRs specific for an antigen) has the ability to
recognize and bind antigen, although at a lower affinity than the entire binding site.
[0030] "Single-chain Fv" also abbreviated as "sFv" or "scFv" are antibody fragments that comprise the VH and VL
antibody domains connected into a single polypeptide chain. Preferably, the sFv polypeptide further comprises a polypep-
tide linker between the VH and VL domains which enables the sFv to form the desired structure for antigen binding.
[0031] The term "diabodies" refers to small antibody fragments prepared by constructing sFv fragments with short
linkers (about 5-10 residues) between the VH and VL domains such that inter-chain but not intra-chain pairing of the V
domains is achieved, resulting in a bivalent fragment, i.e., fragment having two antigen-binding sites. Bispecific diabodies
are heterodimers of two "crossover" sFv fragments in which the VH and VL domains of the two antibodies are present
on different polypeptide chains.
[0032] "Humanized" forms of non-human (e.g., rodent) antibodies are chimeric antibodies that contain minimal se-
quence derived from the non-human antibody. For the most part, humanized antibodies are human immunoglobulins
(recipient antibody) in which residues from a hypervariable region of the recipient are replaced by residues from a
hypervariable region of a non-human species (donor antibody) such as mouse, rat, rabbit or non-human primate having
the desired antibody specificity, affinity, and capability. In some instances, framework region (FR) residues of the human
immunoglobulin are replaced by corresponding non-human residues. Furthermore, humanized antibodies may comprise
residues that are not found in the recipient antibody or in the donor antibody. These modifications are made to further
refine antibody performance. In general, the humanized antibody will comprise substantially all of at least one, and
typically two, variable domains, in which all or substantially all of the hypervariable loops correspond to those of a non-
human immunoglobulin and all or substantially all of the FRs are those of a human immunoglobulin sequence. The
humanized antibody optionally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically
that of a human immunoglobulin.
[0033] An antibody or other organic molecule "which binds" an antigen of interest, e.g. a polypeptide or peptide selected
from SEQ ID NOs: 1 to 5, preferably SEQ ID NOs: 2 to 5, is one that binds the antigen with sufficient affinity such that
the antibody or other organic molecule is useful as a diagnostic agent in a cell, tissue and/or body fluid expressing the
antigen, and does not significantly cross-react with other proteins. In such embodiments, the extent of binding of the
antibody or other organic molecule to a "non-target" protein will be less than about 10% of the binding of the antibody
or other organic molecule to its particular target protein as determined by radioimmunoprecipitation (RIA). With regard
to the binding of an antibody or other organic molecule to a target molecule, the term "specific binding" or "specifically
binds to" or is "specific for" a particular polypeptide or an epitope on a particular polypeptide target means binding that
is measurably different from a non-specific interaction. Specific binding can be measured, for example, by determining
binding of a molecule compared to binding of a control molecule, which generally is a molecule of similar structure that
does not have binding activity. For example, specific binding can be determined by competition with a control molecule
that is similar to the target, for example, an excess of non-labeled target. In this case, specific binding is indicated if the
binding of the labeled target to a probe is competitively inhibited by excess unlabeled target. The term "specific binding"
or "specifically binds to" or is "specific for" a particular polypeptide or an epitope on a particular polypeptide target as
used herein can be exhibited, for example, by a molecule having a Kd for the target of at least about 10-4 M, preferably
at least about 10-5 M, preferably at least about 10-6 M, preferably at least about 10-7 M, preferably at least about 10-8
M, preferably at least about 10-9 M, preferably at least about 10-10 M, preferably at least about 10-11 M, preferably at
least about 10-12 M, or greater. In one embodiment, the term "specific binding" refers to binding where a molecule binds
to a particular polypeptide or epitope on a particular polypeptide without substantially binding to any other polypeptide
or polypeptide epitope.
[0034] The word "label" when used herein refers to a detectable compound or composition which is conjugated directly
or indirectly to the antibody, oligopeptide or other organic molecule so as to generate a "labeled" antibody, oligopeptide
or other organic molecule. The label may be detectable by itself (e.g. radioisotope labels or fluorescent labels) or, in the
case of an enzymatic label, may catalyze chemical alteration of a substrate compound or composition which is detectable.
[0035] The terms "Western blot," "Western immunoblot" "immunoblot" and "Western" refer to the immunological anal-
ysis of protein(s), polypeptides or peptides that have been immobilized onto a membrane support. The proteins are first
resolved by polyacrylamide gel electrophoresis (i.e., SDS-PAGE) to separate the proteins, followed by transfer of the
protein from the gel to a solid support, such as nitrocellulose or a nylon membrane. The immobilized proteins are then
exposed to an antibody having reactivity towards an antigen of interest. The binding of the antibody (i.e., the primary
antibody) is detected by use of a secondary antibody which specifically binds the primary antibody. The secondary
antibody is typically conjugated to an enzyme which permits visualization of the antigen-antibody complex by the pro-
duction of a colored reaction product or catalyzes a luminescent enzymatic reaction (e.g., the ECL reagent, Amersham).
[0036] As used herein, the term "ELISA" refers to enzyme-linked immunosorbent assay (or EIA). Numerous ELISA
methods and applications are known in the art, and are described in many references (See, e.g., Crowther, "Enzyme-
Linked Immunosorbent Assay (ELISA)," in Molecular Biomethods Handbook, Rapley et al. [eds.], pp. 595-617, Humana
Press, Inc., Totowa, N.J. [1998]; Harlow and Lane (eds.), Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory













Press [1988]; Ausubel et al. (eds.), Current Protocols in Molecular Biology, Ch. 11, John Wiley & Sons, Inc., New York
[1994]). In addition, there are numerous commercially available ELISA test systems.
[0037] One ELISA method is a "direct ELISA," where an antigen (e.g., a polypeptide or peptide selected from SEQ
ID NOs: 1 to 5, preferably SEQ ID NOs: 2 to 5) in a sample is detected. In one embodiment of the direct ELISA, a sample
containing antigen is exposed to a solid (i.e., stationary or immobilized) support (e.g., a microtiter plate well). The antigen
within the sample becomes immobilized to the stationary phase, and is detected directly using an enzyme-conjugated
antibody specific for the antigen.
[0038] In an alternative embodiment, an antibody specific for an antigen is detected in a sample. In this embodiment,
a sample containing an antibody (e.g., an antibody specific for a polypeptide or peptide selected from SEQ ID NOs: 1
to 5, preferably SEQ ID NOs: 2 to 5, is immobilized to a solid support (e.g., a microtiter plate well). The antigen-specific
antibody is subsequently detected using purified antigen and an enzyme-conjugated antibody specific for the antigen.
[0039] In another alternative embodiment, an "indirect ELISA" is used. In one embodiment, an antigen (or antibody)
is immobilized to a solid support (e.g., a microtiter plate well) as in the direct ELISA, but is detected indirectly by first
adding an antigen-specific antibody (or antigen), then followed by the addition of a detection antibody specific for the
antibody that specifically binds the antigen, also known as "species-specific" antibodies (e.g., a goat anti-rabbit antibody),
which are available from various manufacturers known to those in the art.
[0040] In other embodiments, a "sandwich ELISA" is used, where the antigen (e.g. contained in a test sample) is
immobilized on a solid support (e.g., a microtiter plate) via an antibody (i.e., a capture antibody) that is immobilized on
the solid support and is able to bind the antigen of interest. Following the affixing of a suitable capture antibody to the
immobilized phase, a sample is then added to the microtiter plate well, followed by washing. If the antigen of interest is
present in the sample, it is bound to the capture antibody present on the support. In some embodiments, a sandwich
ELISA is a "direct sandwich" ELISA, where the captured antigen is detected directly by using an enzyme-conjugated
antibody directed against the antigen. Alternatively, in other embodiments, a sandwich ELISA is an "indirect sandwich"
ELISA, where the captured antigen is detected indirectly by using an antibody directed against the antigen, which is
then detected by another enzyme-conjugated antibody which binds the antigen-specific antibody, thus forming an anti-
body-antigen-antibody-antibody complex. Suitable reporter reagents are then added to detect the third antibody. Alter-
natively, in some embodiments, any number of additional antibodies are added as necessary, in order to detect the
antigen-antibody complex. In some preferred embodiments, these additional antibodies are labelled or tagged, so as to
permit their visualization and/or quantitation.
[0041] As used herein, the term "capture antibody" refers to an antibody that is used in a sandwich ELISA to bind (i.e.,
capture) an antigen in a sample prior to detection of the antigen. For example, in some embodiments, a polyclonal
antibody against a polypeptide or peptide selected from SEQ ID NOs: 1 to 5, preferably SEQ ID NOs: 2 to 5, serves as
a capture antibody when immobilized in a microtiter plate well. This capture antibody binds the polypeptide and/or peptide
present in a sample added to the well. In one embodiment of the present invention, biotinylated capture antibodies are
used in the present invention in conjunction with avidin-coated solid support. Another antibody (i.e., the detection antibody)
is then used to bind and detect the antigen-antibody complex, in effect forming a "sandwich" comprised of antibody-
antigen-antibody (i.e., a sandwich ELISA).
[0042] As used herein, a "detection antibody" is an antibody which carries a means for visualization or quantitation,
which is typically a conjugated enzyme moiety that typically yields a colored or fluorescent reaction product following
the addition of a suitable substrate. Conjugated enzymes commonly used with detection antibodies in the ELISA include
horseradish peroxidase, urease, alkaline phosphatase, glucoamylase and β-galactosidase. In some embodiments, the
detection antibody is directed against the antigen of interest, while in other embodiments, the detection antibody is not
directed against the antigen of interest. In some embodiments, the detection antibody is an anti-species antibody.
Alternatively, the detection antibody is prepared with a label such as biotin, a fluorescent marker, or a radioisotope, and
is detected and/or quantitated using this label.
[0043] As used herein, the terms "reporter reagent," "reporter molecule," "detection substrate" and "detection reagent"
are used in reference to reagents which permit the detection and/or quantitation of an antibody bound to an antigen. For
example, in some embodiments, the reporter reagent is a colorimetric substrate for an enzyme that has been conjugated
to an antibody. Addition of a suitable substrate to the antibody-enzyme conjugate results in the production of a colorimetric
or fluorimetric signal (e.g., following the binding of the conjugated antibody to the antigen of interest). Other reporter
reagents include, but are not limited to, radioactive compounds. This definition also encompasses the use of biotin and
avidin-based compounds (e.g., including but not limited to neutravidin and streptavidin) as part of the detection system.
[0044] As used herein, the term "signal" is used generally in reference to any detectable process that indicates that a
reaction has occurred, for example, binding of antibody to antigen. It is contemplated that signals in the form of radio-
activity, fluorimetric or colorimetric products/reagents will all find use with the present invention. In various embodiments
of the present invention, the signal is assessed qualitatively, while in alternative embodiments, the signal is assessed
quantitatively.
[0045] As used herein, the term "amplifier" is used in reference to a system which enhances the signal in a detection













method, such as an ELISA (e.g., an alkaline phosphatase amplifier system used in an ELISA).
Methods of Detecting Polypeptides
[0046] Polypeptides or peptides of SEQ ID NOs: 1 to 5, preferably SEQ ID NOs: 2 to 5, can be detected, visualized,
determined, quantitated, etc. according to any effective method. Useful methods include, but are not limited to, immu-
noassays, radioimmunoassay (RIA), ELISA, immunofluorescence, flow cytometry, histology, electron microscopy, light
microscopy, in situ assays, immunoprecipitation, Western blot and the like.
[0047] Immunoassays may be carried out in liquid or on a support. For instance, a sample (e.g. blood, urine, tissue,
body fluids, preferably serum) can be brought in contact with and immobilized onto a solid phase support or carrier such
as nitrocellulose or other solid support capable of immobilizing cells, cell particles or soluble proteins. The support may
then be washed with suitable buffers followed by treatment with detectably labeled antibody specifically recognizing a
polypeptide or peptide of SEQ ID NOs: 1 to 5, preferably SEQ ID NOs: 2 to 5. The solid phase support can then be
washed with a buffer a second time to remove unbound antibody. The amount of bound label on the solid support may
then be detected by conventional means.
Diagnosis of a Bone and/or Cartilage Disorder, e.g. osteoarthritis
[0048] The present invention also provides a method of prognosis and/or diagnosing a bone and/or cartilage disorder,
such as osteoarthritis and/or subchondral bone sclerosis, in a mammal, which is based on the decreased expression
and/or concentration of a polypeptide or peptide selected from SEQ ID NOs: 1 to 5, preferably SEQ ID NOs: 2 to 5,
preferably to be measured in serum samples. The present invention provides a valuable clinical marker correlated with
such a disorder.
[0049] Such methods comprise determining if a polypeptide or peptide selected from SEQ ID NOs: 1 to 5, preferably
SEQ ID NOs: 2 to 5, is underexpressed in a test sample as compared to a normal sample. Polypeptides of SEQ ID NOs:
1 to 5, preferably SEQ ID NOs: 2 to 5, are selectively expressed in human bone as shown in the examples of this
application. A decreased presence of a polypeptide or peptide selected from SEQ ID NOs: 1 to 5, preferably SEQ ID
NOs: 2 to 5, in a patient-derived sample indicates osteoarthritis and/or subchondral bone sclerosis. The assay is carried
out using any standard methodology that measures levels (as compared to known normal controls) of a certain protein,
e.g., by Western blot assays or a quantitative assay such as ELISA. For example, a standard competitive ELISA format
using an antibody specific for a polypeptide or peptide selected from SEQ ID NOs: 1 to 5, preferably SEQ ID NOs: 2 to
5, is used to quantify levels of the polypeptide. Alternatively, a sandwich ELISA using a first antibody as the capture
antibody and a second antibody specific for a polypeptide or peptide selected from SEQ ID NOs: 1 to 5, preferably SEQ
ID NOs: 2 to 5, as a detection antibody is used.
[0050] In one embodiment, the method comprises (a) obtaining a test sample from a patient suspected of having a
bone and/or cartilage disorder (b) detecting an expression level of a polypeptide selected from the group consisting of
SEQ ID NOs: 1 to 5, preferably SEQ ID NOs: 2 to 5, by assaying for a polypeptide selected from the group consisting
of SEQ ID NOs: 1 to 5, preferably SEQ ID NOs: 2 to 5; and (c) comparing said level to that of a healthy control, whereby
a decrease in the expression level of a polypeptide selected from the group consisting of SEQ ID NOs: 1 to 5, preferably
SEQ ID NOs: 2 to 5 relative to the level of expression of a polypeptide selected from the group consisting of SEQ ID
NOs: 1 to 5, preferably SEQ ID NOs: 2 to 5, in the control, indicates a positive result for a bone and/or a cartilage disorder
such as osteoarthritis and/or subchondral bone sclerosis.
[0051] The present invention will be described in more detail by the following examples which shall not be understood
as limiting in any way.
Examples
Example 1: Subchondral osteoblasts cell culture
[0052] Tibial subchondral bone plates were obtained from 10 OA men undergoing knee replacement surgery. The
age of the patients ranged from 42 to 83 years. After careful elimination of trabecular bone and articular cartilage, OA
subchondral bone was dissected to separate non sclerotic (NSC) from SC zones. Only the subchondral bone zones
with a thickness greater than 2 mm and either denuded or overlaid by fibrillated cartilage were considered as SC bone.
Also, only the subchondral bone zones with a maximal thickness of 1 mm were considered as NSC bone. Osteoblasts
from SC or NSC subchondral bone were then obtained by outgrowth from explants. At confluence, primary cells were
collected by trypsinization, seeded (50,000 cells/cm2) in 12-well plates (12-well companion plates, Falcon, BD Bioscienc-
es) and grown for 3 days in DMEM containing 10% FBS, 100 U/ml penicillin, 100 mg/ml streptomycin, 10 mM HEPES.
At this stage they were considered as pre-osteoblasts (no alkaline phosphatase activity). Pre-osteoblasts were either













used directly or differentiated in mature osteoblasts, by maintaining for further 14 days in a differentiation media, composed
of DMEM containing 100 U/ml penicillin, 100 mg/ml streptomycin, 10 mM HEPES, 2% Ultroser G, a serum substitute,
10-8 M 1,25-(OH)2-vitamin D3 (Sigma-Aldrich, Belgium), 2 mM glutamine, 50 mg/ml ascorbic acid and 20 mg/ml proline.
At the end of this differentiation period, cells expressed an osteoblast/osteocyte phenotype characterized by the pro-
duction of osteocalcin and alkaline phosphatase, and were able to mineralize their matrix in presence of β-glycerophos-
phate.
[0053] For the experimentations, pre-osteoblasts or mature osteoblasts were rinsed and then cultured in a BSA/FBS
free medium for 72 hours. The nutrient media used was DMEM supplemented with 1% ITS (Lonza, Belgium), 10 mM
HEPES, 100 U/ml penicillin, 100 mg/ml streptomycin, 2mM glutamine (Lonza, Belgium), 50 mg/ml ascorbic acid (Sigma-
Aldrich, Belgium), 20 mg/ml proline (Invitrogen, Belgium). ITS is a premixed cell growth system containing in one ml:
0.625 mg insulin, 0.625 mg transferrin, 0.625 mg selenious acid. These conditioned 72h supernatants were used to
perform the secretome analysis.
Example 2: Proteomic analysis
[0054] A proteomic analysis of osteoarthritic osteoblasts secretome was performed, using differential quantitative and
relative label free analysis on nanoUPLC-Synapt HDMS G2 system (Waters). One patient was used to perform validation
tests before 5 other patients with matched NSC and SC secretome were analyzed.
Protein identification by LC-ESI-MS/MS
[0055] The samples were reduced, alkylated and reduced, concentrated using Amicon (Millipore) with membrane cut-
off of 3kDa. The protein content of the samples was then quantified using RCDC kit (Biorad). Aliquotes of 15 mg for each
sample were reduced, alkylated and reduced, concentrated using Amicon (Millipore) with membrane cut-off of 3kDa,
and then the 2D-Clean up kit (GE) was applied according to manufacturer recommendations, to eliminate impurities not
compatible with mass spectrometry analysis. The protein pellets after the washing steps were further resolubilized in
bicarbonate ammonium 50mM. The samples were digested in solution with trypsin (16 hours at 37°C ratio tryspin/total
proteins (W/W) (1/50), 3h at 37°C with ratio 1/100 in 80% ACN). The reaction was stopped by addition of formic acid.
The samples were evaporated to dryness in a speed vacuum. The samples were redissolved in water 0.1% formic acid
then an aliquote corresponding to 3.5 mg of protein digest for each sample was purified using a Zip-Tip C18 High Capacity
according to manufacturer recommendations. The samples were evaporated to dryness in a speed vacuum.
[0056] The peptides were conditioned at 3.0 mg in ammonium formiate 100mM, with 150fmoles in ADH per volume
injected for the MPDS mix standard (Waters). The internal standards spiked at different ratio between sample spiked
with MPDS mix1 or 2 allows technical verification of the entire 2D-UPLC separation, MS-MSE data acquisition with
additional ion mobility separation, PLGS identification process and also relative quantitative analysis. ADH being present
at ratio MPDS1/MPDS2 = 1.
[0057] Differential quantitative and relative label free analysis on a nanoUPLC-SynaptTM HDMSTM G2 system (Wa-
ters).
[0058] The principle of this method is to compare in a quantitative fashion, tryptic peptides digests of complex samples
and spiked with different commercial internal standards which allows their relative quantification. The high sensitivity,
resolution and mass accuracy of this mass spectrometer that combines high efficiency ion mobility (IMS) and Time of
flight Mass Spectrometry (TOF-MS), together with the statistical software developed by Waters allows confident identi-
fication of the peptides and proteins present in the original peptides mixes to be compared.
[0059] The Synapt TM HDMS TM G2 mass spectrometer uses electropsray ionisation source (ESI) and allows sensitive
detection (lower limit around 0.1 to 1 fmol of protein) with high resolution and high mass accuracy (within 10ppm) for
the analyzed peptides. All the peptides were fragmented (MSE) and their sequence and identity were be obtained after
database searches and correlation to the accurate mass measured for each parent peptide fragmented.
[0060] Statistical analysis with ProteinLynx Global SERVER vs2.5 included identification of the peptides and proteins
and their relative quantification on the base of co-analysis of a second internal standard composed of several proteins
digests, present in both samples to be compared at different abundance ratio. The linear dynamic range of this label
free quantitative technique was around 3 to 4 order of magnitude.
PLGS analysis
[0061] Protein identification was performed using the data base extracted from UNIPROT Sus Crofa with manual
addition of the protein sequences used as spikes and internal standards: MPDS mix.
[0062] The PLGS score is a probabilistic score correlated to the degree of confidence regarding the identification of
a protein. Therefore a high value of PLGS score correlates with the fact that a high quality and quantity of information













was observed by MS and MSE. The score is attributed to the protein after database search. This database search
involves also the search on a randomized database recomputed from the original data base to evaluate the risk of false
positive protein identification. For identification, the minimum to consider is at least two different peptides per protein
identified and to check the false positive rate, this should be as low as possible (the false positive rate will be of maximum
4% because of the settings used in PLGS database search).
[0063] The results show that osteomodulin is more abundant in non sclerotic secretome than in sclerotic secretome.
As mentioned above, the proteomic analysis of osteoarthritic osteoblasts secretome was performed, using differential
quantitative and relative label free analysis on nanoUPLC-Synapt HDMS G2 system (Waters) to discover the differential
protein production between non sclerotic and sclerotic osteoblasts. With this proteomic analysis and using 6 patients,
osteomodulin protein production was found to be 60% lower by sclerotic compared to non sclerotic osteoblasts in 4
patients (p<0.001), while undetectable in the 2 other patients in the sclerotic osteoblasts secretome.
[0064] In addition, different peptide fragments of osteomodulin were found in the proteomic study (fragments A-H)
and matched with data from human body fluid, namely synovial fluid, urine, plasma). The fragments of osteomodulin
and in which test samples they were found are summarized in the following table 1.
Example 3: Expression of osteomodulin in osteoblasts. Measurement by Quantitative Real-time RT PCR.
[0065] In order to show expression of osteomodulin in osteoblasts the mRNA levels of osteomodulin was analyzed in
5 patients. RNA from 1.106 cells was isolated by RNeasy mini kit total RNA isolation system (Qiagen, Belgium) and
polymerase chain reaction (PCR) was performed by using the Light Cycler- SYBR premix Ex Taq (Takara, Belgium).
The PCR template source was either 3 ng first-strand cDNA or purified DNA standard. The following primer sequences
were used to amplify the desired cDNA: HPRT forward 5’-TGTAATGACCAGTCAACAGGG-3’ (SEQ ID NO: 6) and
reverse 5’-TGCCTGACCAAGGAAAGC-3’ (SEQ ID NO: 7), Osteomodulin (OMD) forward 5’- TCCTGGTTTGCCTTCT-
TCACTT-3’ (SEQ ID NO: 8) and reverse 5’-GGGTCAATAGAAGGACACATCAC-3’ (SEQ ID NO: 9). Hypoxanthine-
guanine phosphoribosyltransferase (HPRT) was used as an internal standard and the ratio of OMD to HPRT were
calculated. Five patients were analyzed, and four of them are other ones than used in the proteomic analysis.
[0066] The results showed that osteomodulin is less expressed by sclerotic osteoblasts than non sclerotic osteoblasts.
The mRNA levels of osteomodulin was analyzed in 5 patients. As result, a 0.57 +/- 0.19 fold between non sclerotic and
sclerotic pre-osteoblasts (Figure 1, p=0.0306) and 0.66 +/- 0.27 fold between non sclerotic and sclerotic mature oste-
oblasts (Figure 1, p=0.0241) was observed. In figure 1 osteomodulin gene expression by pre-osteoblasts or mature
osteoblasts, in the non sclerotic or sclerotic cells is shown. The mRNA copy numbers were normalized against the
corresponding copy number of HPRT mRNA and results are the mean 6 SEM of five independent experiments performed
with bone biopsy coming from different donors. In each experiment, each experimental condition was performed in
duplicate. Comparison of mean values was performed by paired t-test.
Example 4: Detection of the presence of osteomodulin and osteomodulin fragments in human serum by Western 
blotting
[0067] In order to assess this hypothesis that osteomodulin or osteomodulin fragments are present in the human
serum and could be targeted as biomarker, human serum samples were analyzed by western blot using a goat polyclonal
antiserum raised against the entire osteomodulin protein (R&D systems) in 3 healthy patients and osteoblasts culture
supernatants.
[0068] Serum of 12 men were used in western-blotting experiments, 6 healthy and 6 suffering of severe OA. Before
experiment serum were depleted in IgG and albumin using ProteoPrep kits (Sigma). During this process serum was
diluted by approximately 3.3-fold. Subchondral osteoblast supernatants were 20-fold concentrated using Amicon Ultra
3kDa 2 ml column (Millipore). Depleted serum (15ml) or osteoblasts concentrated supernatant (6 ml = 6 mg total proteins)
Table 1: Fragments of osteomodulin identified by proteomic analysis
fragment amino acid sequence relating to SEQ ID NO: 1 source
F, D and B 131-176 synovial fluid, urine, plasma
G 214-223 urine, plasma
E 269-291 urine, plasma
A 300-314 plasma
H 342-366 plasma













were fractioned by electrophoresis on a polyacrylamide gel (9%) and transferred onto a PVDF membrane. Membranes
were blocked overnight 4°C with Roche Blocking Reagent. Membranes were then incubated overnight at 4°C with a
biotinylated polyclonal goat antiserum, affinity purified, raised against the whole osteomodulin protein (BAF2884, R&D
systems) 1:200 dilution in 0.5% Roche blocking reagent. Streptavidin-Horseradish peroxidase (HRP) (1:2500 dilution)
was used as detection (Roche). The reaction was revealed with Luminata classico Western blotting substrate (Millipore)
and capture with an ImageQuantLAS4000 (Amersham).
[0069] The results of the Western blotting for detecting the presence of osteomodulin and possible osteomodulin
fragments in human serum are shown in Figure 2 (lanes s59, s67, s62). In osteoblasts culture supernatants, the osteo-
modulin secreted appeared in two major bands at approximately 70 and 75 kDa, but with a variated pattern from 65 to
120 kDa probably due to a variation in glycosylation. The osteomodulin band was stronger in non sclerotic (NSC) than
in sclerotic (SC) osteoblasts (Figure 2, lanes NSC and SC). In human serum samples the major form of osteomodulin
protein (detected about 54 kDa) was observed. Minor forms at about 42, 35 and 30 kDa (see arrows in Figure 2) were
also observed, which indicated that fragments of the protein were present in the circulating serum (Figure 2, lanes s59,
s67, s62).
[0070] In Figure 2 the results of the Western-blotting detection of osteomodulin are shown, wherein the different lanes
shown are as follows: rhOMD: human recombinant osteomodulin (positive control), DMEM: concentration unconditioned
culture supernatant (negative control), NSC: non sclerotic osteoblasts supernatant, SC: sclerotic osteoblasts supernatant,
s59, s67, s62 : serum of three healthy patients.
Example 5: ELISA development targeting 2 fragments of osteomodulin
[0071] From the results obtained in Examples 2 and 4 and from datamining, the inventors assumed that the osteo-
modulin is cleaved in several peptides before these peptides arrive in the serum. In view of MMPs prediction cleavage
sites, proteomics studies in biological fluid, and the fact that 70 residues C-terminal are considered to remain into the
bone tissue, linked to the hydroxyapatite, two polypeptides were created and checked as potential biomarkers for oste-
oarthritis, OMD1 131-KIDYGVFAKLPNLLQLHLEHNNLEEFPFPLPKSLERLLLGYNEISKLQTNAMDGLVNL TMLDLCY-
NYLHDSLLKDKIFAKMEKLMQLNLCSNR-223 (SEQ ID NO: 2) and OMD2 236-MYLSLENNSISSIPEKYFDKLPKLHT-
LRMSHNKLQDIPYNIFNLPNIVELSVGHNK LKQAF-296 (SEQ ID NO: 3).
Preparing antisera directed to OMD1 and OMD2
[0072] To verify the hypothesis that osteomodulin fragments could be found in the serum and may serve as biomarker,
BalbC mice were immunized against 2 peptides of osteomodulin, OMD1a (148-LEHNNLEEFPFPLPK-162; SEQ ID NO:
4) and OMD2a (261-LRMSHNKLQDIPYNI-276; SEQ ID NO: 5)-KLH coupled peptides, respectively. The two different
antisera obtained were specific to these sequences and did not show cross-reaction with 60% homolog peptides contained
in the Lumican protein. Further, antiserum directed to OMD2 did not cross react with the sequence 268-290 of osteo-
modulin. Screening were made using biotinylated peptides, without the cysteine added for the KLH coupling, fixed on
a streptavidin-coated 96-wells-plate. The competitive ELISA was carried using unbiotinylated and uncoupled peptide as
competitor, with a standard curve concentrations comprise between 520 nM and 8 nM. Peroxidase AffiniPure Goat Anti-
Mouse IgG, Fcγ Fragment Specific (Jackson ImmunoResearch) was used as secondary antibody (1:10000 dilution).
Human sera dilution was shown to be parallel to the standard curve from 1:2 to 1:8 dilution in Diluent Reagent Buffer
(D-Tek, Belgium). Assays were performed at 1:3 dilution of the sera for human and 1:5 for guinea pig. Culture supernatants
were assayed undiluted.
Example 6: ELISA using human serum for detection of osteomodulin fragments
[0073] The polyclonal antibodies directed to OMD1 and OMD2 prepared in Example 5 were used for detecting possible
osteomodulin fragments in human serum by ELISA. In human serum, OMD1 and OMD2 in 33 healthy and 24 OA patients
were quantified. In the healthy population, 11 were 20-30 years-old, 12 were 31-45-years-old and 10 were 46-65 years-
old. The results are summarized in Figure 4. The age range in OA population was 44-83 years. OMD1 and OMD2 were
both significantly lower in OA compared to healthy patients (p=0.0137 and 0.0013, respectively, figure 4). The levels
were not significantly different between men and women. The OMD1 level was not significantly different regarding age
in healthy patient, but OMD2 level was lower in young 20-30 years-old patients compared to the 31-45 and 46-65-years-
old groups.
Example 7: ELISA using osteoblasts culture supernatant for detection of osteomodulin fragments
[0074] Further an ELISA was carried out using the polyclonal antibodies directed to OMD1 and OMD2 prepared in













Example 5 for detecting possible osteomodulin fragments in osteoblasts culture supernatant. In these ELISA tests
fragments in osteoblasts culture supernatant were detected, and also the decrease of OMD1 and OMD2 in sclerotic
secretome compared to non sclerotic secretome was confirmed. The results are summarized in Figure 3. The figure
shows OMD1 and OMD2 concentration in non sclerotic or sclerotic pre-osteoblasts and osteoblasts culture supernatant.
Means +/-SD from 2 cultures of two independent experiments performed with bone biopsy coming from different donors.
In each experiment, each experimental condition was performed in triplicate. Comparison of mean values was performed
by paired t-test.
Example 8: guinea pig spontaneous model of OA
[0075] Further, OMD1 and OMD2 was assessed in a guinea pig spontaneous model of OA. In this model, guinea pig
developed OA and at 35-week of age animals showed severe OA lesions quantifiable using the OARSI histological
score. 15 animals were used in a control group and 15 animals were treated with a potential anti-OA treatment during
31 weeks. Beside a significant reduction in the histological OA score of the animals, an increase tendency of OMD1 and
OMD2 levels in the serum was observed. The results are summarized in Figure 5. The figure shows the quantification
of OMD1 and OMD2 in OA guinea pig serum, in nM.
SEQUENCE LISTING
[0076]
<110> Université de Liège
<120> Osteomodulin and osteomodulin fragments as biomarkers for













































































































gggtcaatag aaggacacat cac 23
Claims
1. Use of Osteomodulin (OMD) protein or fragment of osteomodulin (OMD) protein in in-vitro prognosis and/or diagnosis
of osteoarthritis and/or subchondral bone sclerosis of mammals, preferably human individuals wherein full-length
osteomodulin protein is having the amino acid sequence shown in SEQ ID NO: 1,













wherein osteomodulin (OMD) protein is a protein represented by the amino acid positions 1-421 or by the amino
acid positions 21-421 of SEQ ID NO: 1; and
wherein said fragment is selected from the group consisting of a) and b)
a) OMD-(131-223),
b) OMD-(236-296).
2. Use of Osteomodulin (OMD) protein or fragment of osteomodulin (OMD) protein according to claim 1, wherein
decreased expression or decreased concentration in body fluids of said osteomodulin protein or its fragment(s)
compared to healthy individuals indicate onset of osteoarthritis and/or subchondral bone sclerosis.
3. Use of Osteomodulin (OMD) protein or fragment of osteomodulin (OMD) protein according to claim 2, wherein said
decreased expression or decreased concentration is measured in a body fluid selected from the group consisting
of urine, secretions, interstitial fluid, blood, synovial fluid, serum, spinal fluid lymph, preferably serum.
4. Method for in-vitro prognosis and/or diagnosis of osteoarthritis and/or subchondral bone sclerosis, comprising the
following steps:
i) measuring osteomodulin (OMD) protein or a fragment or fragments of osteomodulin (OMD) protein in samples
of body fluids of mammalian individuals, preferably human serum samples;
ii) judging that decreased levels of osteomodulin (OMD) protein or of said fragment(s) compared to levels in
body fluids, preferably serum, of healthy individuals indicate onset of osteoarthritis and/or subchondral bone
sclerosis
wherein full-length osteomodulin protein is having the amino acid sequence shown in SEQ ID NO: 1,
wherein osteomodulin (OMD) protein is a protein represented by the amino acid positions 1-421 or by the amino
acid positions 21-421 of SEQ ID NO: 1; and
wherein said fragment is selected from the group consisting of a) and b)
a) OMD-(131-223),
b) OMD-(236-296).
5. Method for in-vitro determining or checking or diagnosis of the therapeutic effect of treatment of osteoarthritis and/or
subchondral bone sclerosis in a mammalian individual, preferably a human individual, comprising the following steps:
i) measuring osteomodulin (OMD) protein or a fragment or fragments of osteomodulin (OMD) protein in samples
of body fluids, preferably serum samples, of said individual during or after treatment;
ii) judging that either one of (1) to (3)
(1) normal levels of osteomodulin (OMD) protein or of said fragment(s) in the samples obtained in step i), or
(2) increased levels of osteomodulin (OMD) protein or of said fragment(s) in said samples obtained in step
i) compared to levels in samples of body fluids, preferably serum samples, of said individual before said
treatment, or
(3) increased levels of osteomodulin (OMD) protein or of said fragment(s) in said samples obtained in step
i) compared to levels in samples of body fluids, preferably serum samples, of healthy individuals,
indicate a therapeutic effect of the treatment of osteoarthritis and/or subchondral bone sclerosis in said individual
wherein full-length osteomodulin protein is having the amino acid sequence shown in SEQ ID NO: 1,
wherein osteomodulin (OMD) protein is a protein represented by the amino acid positions 1-421 or by the amino
acid positions 21-421 of SEQ ID NO: 1; and
wherein said fragment is selected from the group consisting of a) and b)
a) OMD-(131-223),
b) OMD-(236-296).
6. Fragment of osteomodulin protein, wherein full-length osteomodulin protein is having the amino acid sequence
shown in SEQ ID NO: 1, and wherein said fragment is selected from the group consisting a) to b):















7. Use of Immunological binding partner specifically binding to osteomodulin (OMD) protein or fragment of osteomodulin
(OMD) protein in in-vitro prognosis and/or diagnosis of osteoarthritis and/or subchondral bone sclerosis of mammals,
preferably human individuals;
wherein full-length osteomodulin protein is having the amino acid sequence shown in SEQ ID NO: 1, and wherein
said fragment is selected from the group consisting of a) to b):
a) OMD-(131-223),
b) OMD-(236-296).
8. Immunological binding partner specifically binding to an osteomodulin fragment, wherein full-length osteomodulin
protein is having the amino acid sequence shown in SEQ ID NO: 1, and wherein said fragment is selected from the
group consisting a) to b):
a) OMD-(131-223),
b) OMD-(236-296).
9. Use of a kit comprising the immunological binding partner according to anyone of claims 7 to 8, in in-vitro prognosis
and diagnosis of osteoarthritis and/or subchondral bone sclerosis of mammals;
wherein said immunological binding partner preferably is selected from the group consisting of polyclonal antibodies,
monoclonal antibodies, humanized antibodies, Fc fragments, Fab fragments, single chain antibodies (scFv), chimeric
antibodies, biobetters and other antigen-specific antibody fragments.
Patentansprüche
1. Verwendung von Osteomodulin-(OMD)-Protein oder eines Fragments des Osteomodulin-(OMD)-Proteins bei der
In-vitro-Prognose und/oder -Diagnose von Osteoarthritis und/oder subchondraler Knochensklerose von Säugetie-
ren, vorzugsweise menschlichen Individuen, wobei das Osteomodulinprotein voller Länge die in SEQ ID NO: 1
gezeigte Aminosäuresequenz aufweist,
wobei das Osteomodulin-(OMD)-Protein ein Protein ist, das durch die Aminosäurepositionen 1-421 oder durch die
Aminosäurepositionen 21-421 von SEQ ID NO: 1 dargestellt wird; und
wobei das Fragment ausgewählt ist aus der Gruppe bestehend aus a) und b)
a) OMD-(131-223),
b) OMD-(236-296).
2. Verwendung von Osteomodulin-(OMD)-Protein oder eines Fragmentes des Osteomodulin-(OMD)-Proteins nach
Anspruch 1, wobei eine verringerte Expression oder verringerte Konzentration des Osteomodulinproteins oder
seines Fragmentes/seiner Fragmente in Körperflüssigkeiten im Vergleich zu gesunden Individuen den Beginn von
Osteoarthritis und/oder subchondraler Knochensklerose anzeigt.
3. Verwendung von Osteomodulin-(OMD)-Protein oder eines Fragmentes des Osteomodulin-(OMD)-Proteins nach
Anspruch 2, wobei die verringerte Expression oder verringerte Konzentration in einer Körperflüssigkeit gemessen
wird, ausgewählt aus der Gruppe bestehend aus Urin, Sekreten, interstitieller Flüssigkeit, Blut, Synovialflüssigkeit,
Serum, Lymphe der Rückenmarksflüssigkeit, vorzugsweise Serum.
4. Verfahren zur In-vitro-Prognose und/oder -Diagnose von Osteoarthritis und/oder subchondraler Knochensklerose,
umfassend die folgenden Schritte:
i) Messen des Osteomodulin-(OMD)-Proteins oder eines Fragments oder von Fragmenten des Osteomodu-
lin-(OMD)-Proteins in Proben von Körperflüssigkeiten von Säugetieren, vorzugsweise Humanserumproben;
ii) Beurteilen, dass verringerte Spiegel von Osteomodulin-(OMD)-Protein oder des Fragments/der Fragmente
im Vergleich zu Spiegeln in Körperflüssigkeiten, vorzugsweise Serum, von gesunden Individuen auf den Beginn
von Osteoarthritis und/oder subchondraler Knochensklerose hinweisen,













wobei das Osteomodulinprotein voller Länge die in SEQ ID NO: 1 gezeigte Aminosäuresequenz aufweist,
wobei das Osteomodulin-(OMD)-Protein ein Protein ist, das durch die Aminosäurepositionen 1-421 oder durch die
Aminosäurepositionen 21-421 von SEQ ID NO: 1 dargestellt wird; und
wobei das Fragment ausgewählt ist aus der Gruppe bestehend aus a) und b)
a) OMD-(131-223),
b) OMD-(236-296).
5. Verfahren zur In-vitro-Bestimmung oder -Überprüfung oder -Diagnose der therapeutischen Wirkung der Behandlung
von Osteoarthritis und/oder subchondraler Knochensklerose bei einem Säugetier, vorzugsweise einem menschli-
chen Individuum, umfassend die folgenden Schritte:
i) Messen des Osteomodulin-(OMD)-Proteins oder eines Fragments oder von Fragmenten des Osteomodu-
lin-(OMD)-Proteins in Proben von Körperflüssigkeiten, vorzugsweise Serumproben, des Individuums während
oder nach der Behandlung;
ii) Beurteilen, dass einer der (1) bis (3)
(1) normale Spiegel des Osteomodulin-(OMD)-Proteins oder des Fragments/der Fragmente in den in Schritt
i) erhaltenen Proben, oder
(2) erhöhte Spiegel des Osteomodulin-(OMD)-Proteins oder des Fragments/der Fragmente in den in Schritt
i) erhaltenen Proben im Vergleich zu Spiegeln in Proben von Körperflüssigkeiten, vorzugsweise Serum-
proben, des Individuums vor der Behandlung, oder
(3) erhöhte Spiegel des Osteomodulin-(OMD)-Proteins oder des Fragments/der Fragmente in den in Schritt
i) erhaltenen Proben im Vergleich zu Spiegeln in Proben von Körperflüssigkeiten, vorzugsweise Serum-
proben, von gesunden Individuen,
eine therapeutische Wirkung der Behandlung von Osteoarthritis und/oder subchondraler Knochensklerose bei
der Person anzeigt,
wobei das Osteomodulinprotein voller Länge die in SEQ ID NO: 1 gezeigte Aminosäuresequenz aufweist,
wobei das Osteomodulin-(OMD)-Protein ein Protein ist, das durch die Aminosäurepositionen 1-421 oder durch
die Aminosäurepositionen 21-421 von SEQ ID NO: 1 dargestellt wird; und
wobei das Fragment ausgewählt ist aus der Gruppe bestehend aus a) und b)
a) OMD-(131-223),
b) OMD-(236-296).
6. Fragment des Osteomodulinproteins, wobei das Osteomodulinprotein voller Länge die in SEQ ID NO: 1 gezeigte
Aminosäuresequenz aufweist, und
wobei das Fragment ausgewählt ist aus der Gruppe bestehend aus a) bis b):
a) OMD-(131-223),
b) OMD-(236-296).
7. Verwendung eines immunologischen Bindungspartners, der spezifisch an das Osteomodulin-(OMD)-Protein oder
ein Fragment des Osteomodulin-(OMD)-Proteins bindet, bei der In-vitro-Prognose und/oder -Diagnose von Oste-
oarthritis und/oder subchondraler Knochensklerose von Säugetieren, vorzugsweise menschlichen Individuen;
wobei das Osteomodulinprotein voller Länge die in SEQ ID NO: 1 gezeigte Aminosäuresequenz aufweist, und wobei
das Fragment ausgewählt ist aus der Gruppe bestehend aus a) bis b):
a) OMD-(131-223),
b) OMD-(236-296).
8. Immunologischer Bindungspartner, der spezifisch an ein Osteomodulinfragment bindet, wobei das Osteomodulin-
protein voller Länge die in SEQ ID NO: 1 gezeigte Aminosäuresequenz aufweist und wobei das Fragment ausgewählt
ist aus der Gruppe bestehend aus a) bis b):
a) OMD-(131-223),
b) OMD-(236-296).













9. Verwendung eines Kits, umfassend den immunologischen Bindungspartner nach einem der Ansprüche 7 bis 8, bei
der In-vitro-Prognose und -Diagnose von Osteoarthritis und/oder subchondraler Knochensklerose von Säugetieren;
wobei der immunologische Bindungspartner vorzugsweise ausgewählt ist aus der Gruppe bestehend aus polyklo-
nalen Antikörpern, monoklonalen Antikörpern, humanisierten Antikörpern, Fc-Fragmenten, Fab-Fragmenten, Ein-
zelketten-Antikörpern (scFv), chimären Antikörpern, Biobetters und anderen Antigen-spezifischen Antikörperfrag-
menten.
Revendications
1. Utilisation de protéine d’ostéomoduline (OMD) ou d’un fragment de protéine d’ostéomoduline (OMD) dans le pro-
nostic et/ou le diagnostic in vitro d’arthrose et/ou de sclérose osseuse sous-chondrale de mammifères, de préférence
des individus humains, la protéine d’ostéomoduline de pleine longueur ayant la séquence d’acides aminés décrite
dans SEQ ID NO : 1,
dans laquelle la protéine d’ostéomoduline (OMD) est une protéine représentée par les positions d’acide aminé 1-421
ou par les positions d’acide aminé 21-421 de SEQ ID NO : 1 ; et
dans laquelle ledit fragment est choisi dans le groupe constitué de a) et b)
a) OMD-(131-223),
b) OMD-(236-296).
2. Utilisation de protéine d’ostéomoduline (OMD) ou d’un fragment de protéine d’ostéomoduline (OMD) selon la re-
vendication 1, dans laquelle l’expression réduite ou la concentration réduite dans des fluides corporels de ladite
protéine d’ostéomoduline ou de son ou ses fragment(s) par rapport à des individus sains indique l’apparition d’arth-
rose et/ou de sclérose osseuse sous-chondrale.
3. Utilisation de protéine d’ostéomoduline (OMD) ou d’un fragment de protéine d’ostéomoduline (OMD) selon la re-
vendication 2, dans laquelle ladite expression réduite ou concentration réduite est mesurée dans un fluide corporel
choisi dans le groupe constitué de l’urine, des sécrétions, un liquide interstitiel, le sang, le liquide synovial, le sérum,
le liquide céphalorachidien, la lymphe, de préférence le sérum.
4. Procédé pour le pronostic et/ou le diagnostic in vitro d’arthrose et/ou de sclérose osseuse sous-chondrale, com-
prenant les étapes suivantes :
i) mesure de protéine d’ostéomoduline (OMD) ou d’un fragment ou de fragments de protéine d’ostéomoduline
(OMD) dans des échantillons de fluides corporels d’individus mammifères, de préférence des échantillons de
sérum humain ;
ii) jugement du fait que des taux réduits de protéine d’ostéomoduline (OMD) ou dudit/desdits fragment(s) par
rapport à des taux dans des fluides corporels, de préférence le sérum, d’individus sains indiquent ou non
l’apparition d’arthrose et/ou de sclérose osseuse sous-chondrale
dans lequel la protéine d’ostéomoduline de pleine longueur a la séquence d’acides aminés décrite dans SEQ ID
NO : 1,
dans lequel la protéine d’ostéomoduline (OMD) est une protéine représentée par les positions d’acide aminé 1-421
ou par les positions d’acide aminé 21-421 de SEQ ID NO : 1 ; et
dans lequel ledit fragment est choisi dans le groupe constitué de a) et b)
a) OMD-(131-223),
b) OMD-(236-296).
5. Procédé in vitro de détermination ou vérification ou diagnostic de l’effet thérapeutique du traitement de l’arthrose
et/ou de la sclérose osseuse sous-chondrale chez un individu mammifère, de préférence un individu humain, com-
prenant les étapes suivantes :
i) mesure de protéine d’ostéomoduline (OMD) ou d’un fragment ou de fragments de protéine d’ostéomoduline
(OMD) dans des échantillons de fluides corporels, de préférence des échantillons de sérum, dudit individu
pendant ou après le traitement ;
ii) jugement du fait que l’un quelconque de (1) à (3)













(1) des taux normaux de protéine d’ostéomoduline (OMD) ou dudit/desdits fragment(s) dans les échantillons
obtenus dans l’étape i), ou
(2) des taux augmentés de protéine d’ostéomoduline (OMD) ou dudit/desdits fragment(s) dans lesdits
échantillons obtenus dans l’étape i) par rapport à des taux dans des échantillons de fluides corporels, de
préférence des échantillons de sérum, dudit individu avant ledit traitement, ou
(3) des taux augmentés de protéine d’ostéomoduline (OMD) ou dudit/desdits fragment(s) dans lesdits
échantillons obtenus dans l’étape i) par rapport à des taux dans des échantillons de fluides corporels, de
préférence des échantillons de sérum, d’individus sains,
indiquent ou non un effet thérapeutique du traitement de l’arthrose et/ou de la sclérose osseuse sous-chondrale
chez ledit individu
la protéine d’ostéomoduline de pleine longueur ayant la séquence d’acides aminés décrite dans SEQ ID NO : 1,
dans lequel la protéine d’ostéomoduline (OMD) est une protéine représentée par les positions d’acide aminé
1-421 ou par les positions d’acide aminé 21-421 de SEQ ID NO : 1 ; et
dans lequel ledit fragment est choisi dans le groupe constitué de a) à b) :
a) OMD-(131-223),
b) OMD-(236-296).
6. Fragment de protéine d’ostéomoduline, la protéine d’ostéomoduline de pleine longueur ayant la séquence d’acides
aminés décrite dans SEQ ID NO : 1, et ledit fragment étant choisi dans le groupe constitué de a) à b) :
a) OMD-(131-223),
b) OMD-(236-296).
7. Utilisation d’un partenaire de liaison immunologique se liant spécifiquement à une protéine d’ostéomoduline (OMD)
ou un fragment de protéine d’ostéomoduline (OMD) dans le pronostic et/ou le diagnostic in vitro d’arthrose et/ou
de sclérose osseuse sous-chondrale de mammifères, de préférence des individus humains ;
dans laquelle la protéine d’ostéomoduline de pleine longueur a la séquence d’acides aminés décrite dans SEQ ID
NO : 1, et dans laquelle ledit fragment est choisi dans le groupe constitué de a) à b) :
a) OMD-(131-223),
b) OMD-(236-296).
8. Partenaire de liaison immunologique se liant spécifiquement à un fragment d’ostéomoduline, la protéine d’ostéo-
moduline de pleine longueur ayant la séquence d’acides aminés décrite dans SEQ ID NO : 1, et ledit fragment étant
choisi dans le groupe constitué de a) à b) :
a) OMD-(131-223),
b) OMD-(236-296).
9. Utilisation d’un kit comprenant le partenaire de liaison immunologique selon l’une quelconque des revendications
7 à 8, dans le pronostic et le diagnostic in vitro de l’arthrose et/ou de la sclérose osseuse sous-chondrale de
mammifères ; dans laquelle ledit partenaire de liaison immunologique est de préférence choisi dans le groupe
constitué d’anticorps polyclonaux, anticorps monoclonaux, anticorps humanisés, fragments Fc, fragments Fab,
anticorps monocaténaires (scFv), anticorps chimériques, biosupérieurs (« biobetters ») et autres fragments d’anti-
corps spécifiques à un antigène.
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